CDEK by Data4ThePeople
Drugs
Search by NameFDA Approval TrendsAdvanced SearchFDA Approved Drugs
Organizations
Search by NameOrganization TrendsAdvanced Search
IndicationsMechanismsTrialsFDA Approvals
About
About CDEKGlossaryAdvanced Search GuideSearch by Name
Drugs
Search by NameFDA Approval TrendsAdvanced SearchFDA Approved Drugs
Organizations
Search by NameOrganization TrendsAdvanced Search
IndicationsMechanismsTrialsFDA Approvals
About
About CDEKGlossaryAdvanced Search GuideSearch by Name
← All indications

Leukemia, Prolymphocytic, B-Cell

A neoplasm of prolymphocytes affecting the blood, bone marrow, and spleen. It is characterized by prolymphocytes exceeding 55% of the lymphoid cells in the blood and profound splenomegaly.

Drugs by status

Phase 2 trials (16)

  • entospletinib
  • obinutuzumab
  • tacrolimus
  • carmustine
  • allogeneic hematopoietic stem cells
  • cyclosporine
  • mycophenolate
  • cyclophosphamide
  • cd19 car-t cells
  • pcar-019
  • fludarabine
  • etoposide
  • cytarabine
  • melphalan
  • letermovir
  • autologous hematopoietic stem cells

Phase 1 trials (6)

  • autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
  • bendamustine
  • lenalidomide
  • ibrutinib
  • pevonedistat
  • anti-cd19/cd20/cd22 car t-cells

Organizations

Organization Involved with Phase 2 Indications (7)

  • PersonGen BioTherapeutics (Suzhou) Co., Ltd.
  • National Cancer Institute (NCI)
  • Anhui Medical University
  • University of Washington
  • Ohio State University
  • Oregon Health and Science University
  • Hefei University

Organization Involved with Phase 1 Indications (3)

  • City of Hope National Medical Center
  • University of Colorado
  • OHSU Knight Cancer Institute

ICD-10 crosswalk

  • C91.30 — Prolymphocytic leukemia of B-cell type not having achieved remission

CDEK

The Clinical Drug Experience Knowledgebase — tracking drugs, sponsoring organizations, and clinical trials from first-in-human testing through approval.

Browse

  • Drugs
  • Organizations
  • Trials

About

  • About CDEK
  • Glossary

Built and maintained by Data4ThePeople.

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED "AS IS", WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.